Navigation Links
Warner Chilcott Announces FDA Approval of New Oral Contraceptive
Date:10/22/2010

licies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded pharmaceuticals business from The Procter and Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009, and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.  In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur.  We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
2. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
3. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
4. Warner Chilcott Announces FDA Approval of Next Generation Actonel
5. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
6. Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex®
7. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
8. Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®
9. Warner Chilcott to Present at UBS Global Life Sciences Conference
10. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
11. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014   GS1 US ... to implement GS1 Standards to support the 2013 ... patient safety and security in the pharmaceutical supply ... Standards to U.S. Pharmaceutical Supply Chain Business Processes ... , was developed in collaboration with GS1 ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... announced that it has earned a $4 million ... AKAO ) associated with the initiation of a ... serious multi-drug resistant (MDR), gram-negative bacterial infections.  The ... study to evaluate the efficacy and safety of ...
(Date:9/17/2014)... Sept. 17, 2014 Sutro Biopharma, a biopharmaceutical ... the biopharmaceutical division of Merck KGaA, Darmstadt, ... the United States and ... license agreement to develop antibody drug conjugates (ADCs). ADCs ... drug. The antibody is thought to specifically target and ...
Breaking Medicine Technology:New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... Nov. 2, 2010 GeNO LLC ( www.genollc.com ... announced today that it has submitted an Investigational ... and Drug Administration (FDA) for the GeNO NITROsyl ... pulmonary hypertension in patients with pulmonary arterial hypertension ...
... , a drug research and development company focused on the ... awarded a grant by the United States government under the ... of its lead product CM-AT for autism.  CM-AT is presently ... US. The QTDP grant program provides support for ...
Cached Medicine Technology:GeNO LLC Submits Investigational New Drug Application for Its NITROsyl™ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension 2GeNO LLC Submits Investigational New Drug Application for Its NITROsyl™ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension 3Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant 2
(Date:9/17/2014)... Boston Children’s Museum and From the ... series, introducing young Museum visitors to musicians from ... national platform celebrating the stories, talents, and character ... musicians featured will also be showcased on NPR's ... fortunate to partner with the wonderful musicians of ...
(Date:9/17/2014)... 2014 Why are Asian Americans at higher risk ... prone to develop the disease at lower body weights? ... transition from traditional high-fiber, low-fat Asian diets to current ... of Asian heritage, says George King, M.D., Senior Vice ... and the senior author of the study. , A ...
(Date:9/17/2014)... Leading eco-friendly beauty brand , Lotus Moon, ... vegan and gluten-free Sugar Cane Fruit Mask. Their newest ... skincare testers were looking for. , “My goal ... that provided results, and I think I accomplished it,” ... Mask combines Willow bark (Salix Alba extract), a natural ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced ... Oral Health Foundation: America’s ToothFairy (NCOHF) to support oral ... Health Zone Program® in California. , The Orange County ... of local constituent groups and stakeholders in a comprehensive ... and its devastating effects on local families. The support ...
(Date:9/17/2014)... Managing diabetes, quitting smoking, controlling high blood pressure, exercising ... for dementia -- even late in life, according to ... commissioned by Alzheimer,s Disease International, revealed that diabetes can ... study noted that obesity and an inactive lifestyle are ... blood pressure. The researchers suggested that dementia ...
Breaking Medicine News(10 mins):Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3
... doing away with the user charges imposed on patients at ... senior CPI(M) MP said today. ,This was conveyed to ... Basudeb Acharia when they called on Prime Minister Manmohan Singh ... Nirmala Deshpande and Hannan Mollah, met the Prime Minister weeks ...
... next week to repair a tennis elbow injury that has ... African vice-captain was forced out of last year's tour of ... the tour of Sri Lanka in August., ,'However, he ... in India in September and the 2007 World Cup in ...
... Intelligence arrested three persons, including the Managing Director ... alleged illegal export of Ephedrine tablets, a controlled ... Substances (NDPS) Act, 1985. ,According to ... persons have been remanded to judicial custody by ...
... by the Johns Hopkins researchers it is found that ... brain which controls// the muscle movements is responsible for ... research is Professor Reza Shadmehr and he and his ... PLoS Biology. This study would help to change the ...
... Royal Brisbane and Women's Hospital (RBWH), Sydney struggles with ... in three wards were found with a bacterium ... skin. ,To prevent the spread, 12 patients ... cent burns) were shifted to Sydney hospital and some ...
... the city, joined by members of Medical Representatives Association ... protest the Centre's reservation// proposals, affecting heatlh services in ... a number of women and ayurvedic doctors, also took ... to Prime Minister Manmohan Singh to the Deputy Commissioner, ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: